Product Description
for Benign Prostatic Hyperplasia (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00077012)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novelion Therapeutics
Company Location: VANCOUVER A1 V6B 0M3
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Prostatic Hyperplasia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BPH 002 | P2 |
Completed |
Prostatic Hyperplasia |
2005-05-01 |